Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells in Patients With Recurrent Implantation Failure: A Systematic Review and Meta-Analysis Publisher Pubmed



Malekihajiagha A1 ; Razavi M2 ; Rezaeinejad M3 ; Rouholamin S4 ; Almasihashiani A5 ; Pirjani R6 ; Sepidarkish M7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Development Center, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Pregnancy health research center, Department of Obstetrics and Gynecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
  3. 3. Department of Obstetrics and Gynecology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran
  6. 6. Obstetrics and Gynecology Department, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran

Source: Journal of Reproductive Immunology Published:2019


Abstract

Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC) has been proposed to improve implantation rates in women with recurrent implantation failure (RIF). The objective of this study was to evaluate whether intrauterine administration of PBMC improves clinical pregnancy and live birth in couples with RIF. Various databases were searched including Medline, Embase, Scopus, Web of Science and Cochrane Central Register of Controlled Trials up to April 2018. This review included all studies that compared intervention of PBMC in infertile women undergoing any form of assisted reproductive technology (ART). Two independent reviewers assessed eligibility; methodological quality; and extracted data. Meta-analysis using a random-effects model was performed to calculate the pooled estimates. Eight studies involving 886 patients were included. The probability of clinical pregnancy was significantly higher in women who received PBMC compared with control (RR: 1.92, 95% CI: 1.48–2.49; P < 0.001). No difference was observed in the studies that transmitted the embryo at blastocyst (RR: 2.44, 95% CI: 1.42–4.20; P = 0.001), or cleavage stage (RR: 2.01, 95% CI: 1.36–2.96; P < 0.001). There was no difference between studies that transmitted the embryo in fresh (RR: 2.14, 95% CI: 1.38–3.32; P < 0.001), or frozen condition (RR: 1.79, 95% CI: 1.32–2.43; P < 0.001). The probability of live birth was significantly higher in women who received PBMC compared with control (RR: 1.93, 95% CI: 1.35–2.76; P < 0.001). Administration of PBMC, irrespective of embryo stage and cycle type, increases clinical pregnancy and live birth in patients experienced RIF. However, these overall estimates should be considered with caution due to the small number, quasi-experimental design and poor quality of most included studies. © 2019 Elsevier B.V.
2. Research Update for Articles Published in Ejci in 2015, European Journal of Clinical Investigation (2017)
Experts (# of related papers)